In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Biotherapy and Radiopharmaceuticals

• Publication date

  2005-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1089/cbr.2005.20.239PMID 15989469
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).

  2004cited by this paper
• Selection and characterization of HER2/neu-binding affibody ligands.

  2004cited by this paper
• HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

  2004cited by this paper
• A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.

  2003cited by this paper
• Zinc-Based Fixative Improves Preservation of Genomic DNA and Proteins in Histoprocessing of Human Tissues

  2003cited by this paper
• Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF

  2003cited by this paper
• Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

  2002cited by this paper
• The Four-State Equilibrium Unfolding of a scFv Antibody Fragment

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

  2001cited by this paper
• The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

  2000cited by this paper
• Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.

  2000cited by this paper
• Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo

  2000cited by this paper
• High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

  1999cited by this paper
• Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells

  1999cited by this paper
• Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.

  1999cited by this paper
• Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling.

  1999cited by this paper
• Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain

  1997cited by this paper
• Radioiodinated antibody targeting of the HER-2/neu oncoprotein.

  1997cited by this paper
• Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.

  1995cited by this paper
• Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy

  1993cited by this paper
• Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

  1992cited by this paper
• Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.

  1991cited by this paper
• A comparison of strategies to stabilize immunoglobulin Fv-fragments.

  1990cited by this paper
• Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

  1990cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990cited by this paper
• Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer.

  1989cited by this paper
• pUR 250 allows rapid chemical sequencing of both DNA strands of its inserts.

  1982cited by this paper
• Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells.

  1980cited by this paper

• Modular Platform for Efficient Assembly of Multifunctional Antibodies Using Orthogonal Protein–Protein Interactions

  2025cites this paper
• N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan

  2025cites this paper
• Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma

  2024cites this paper
• Evaluation of homodimer ^99mTc-HYNIC-E(SSSLTVPWY)_2 peptide on HER2-over expressed breast cancer cells

  2023cites this paper
• Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy

  2022cites this paper
• Homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide improved HER2-overexpressed tumor targeting and imaging

  2022cites this paper
• Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer

  2022cites this paper
• Homomultimer strategy for improvement of radiolabeled peptides and antibody fragments in tumor targeting.

  2022cites this paper
• Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules

  2020cites this paper
• Affibody Molecules as Targeting Vectors for PET Imaging

  2020cites this paper
• Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2

  2019influential citation
• Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

  2019cites this paper
• Correlative Light‐ and Liquid‐Phase Scanning Transmission Electron Microscopy for Studies of Protein Function in Whole Cells

  2019cites this paper
• Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.

  2019cites this paper
• Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line

  2019cites this paper
• Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake

  2019cites this paper
• Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2‐expressing tumours

  2019cites this paper
• Membrane protein stoichiometry studied in intact mammalian cells using liquid-phase electron microscopy.

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 258 Affibody Molecules for HER 3-targeted Theranostics of Malignant Tumours

  2018cites this paper
• Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

  2018cites this paper
• Membrane protein stoichiometry studied in intact mammalian cells using liquid‐phase electron microscopy

  2018cites this paper
• Beyond Antibodies: Engineered Protein Scaffolds for Therapeutic Development

  2017cites this paper
• Development of ADAPT-based tracers for radionuclide molecular imaging of cancer

  2017cites this paper
• A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

  2017influential citation
• Membrane protein stoichiometry studied in intact mammalian cells

  2016cites this paper
• Protein and Peptide Scaffolds and Matrices for Cell Cultures

  2015cites this paper
• Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).

  2015cites this paper
• Affibody Molecules for PET Imaging

  2015cites this paper
• Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity

  2015cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1125 Affibody Molecules for PET Imaging

  2015cites this paper
• HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor.

  2015cites this paper
• Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors

  2015influential citation
• Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy

  2015cites this paper
• Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy

  2015cites this paper
• Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Non‐Antibody Scaffolds as Alternative Therapeutic Agents

  2014cites this paper
• Imaging EGFR and HER2 by PET and SPECT: A Review

  2014cites this paper
• Engineered Affibodies in Translational Medicine

  2014cites this paper
• DONG LIN NEW GENERATION AFFIBODY MOLECULE PHAGE LIBRARY FOR HIGHLY STRINGENT BINDER SELECTIONS

  2014cites this paper
• NextGen protein design.

  2013cites this paper
• Generation and characterization of Affibody molecules targeting HER3

  2013cites this paper
• Protein Engineering: New Approaches and Applications

  2013cites this paper
• Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target

  2013cites this paper
• Breaking New Therapeutic Grounds: Fusion Proteins of Darpins and Other Nonantibody Binding Proteins

  2013cites this paper
• Cysteine-terminated B-domain of Staphylococcus aureus protein A as a scaffold for targeting GABA(A) receptors.

  2013cites this paper
• Protéines de liaison comportant au moins deux domaines de liaison ciblant HER2

  2012cites this paper
• 16 Targeting EGFR and HER 2 for Molecular Imaging of Cancer

  2012cites this paper
• Comparative binding of disulfide-bridged PEG-Fabs.

  2012cites this paper
• An Engineered Affinity Protein-affibody: An Engineered Affinity Protein-affibody

  2012cites this paper
• Engineering of affibody molecules for therapy and diagnostics.

  2012cites this paper
• Targeting EGFR and HER2 for Molecular Imaging of Cancer

  2012cites this paper
• EGFR- and HER2-Binding Affibody Molecules : Cellular studies of monomeric, dimeric and bispecific ligands

  2011cites this paper
• Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).

  2011cites this paper
• Directed evolution and structural analysis of an OB-fold domain towards a specifc binding reagent

  2011cites this paper
• Protein targeting constructs in alpha therapy.

  2011cites this paper
• Protein-based tumor molecular imaging probes

  2011cites this paper
• Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets.

  2010cites this paper
• Antibody Engineering: Optimizing the Delivery Vehicle

  2010cites this paper
• 64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors

  2010cites this paper
• Radionuclide molecular imaging using Affibody molecules.

  2010cites this paper
• Applications of molecular imaging.

  2010cites this paper
• CHAPTER 1 Antibody Engineering : Optimizing the Delivery Vehicle

  2010cites this paper
• The role of HER2 in cancer therapy and targeted drug delivery.

  2010cites this paper
• The Radiopharmaceutical Science of Monoclonal Antibodies and Peptides for Imaging and Targeted In Situ Radiotherapy of Malignancies

  2010cites this paper
• The Radiochemistry of Monoclonal Antibodies and Peptides

  2010cites this paper
• Phage display and molecular imaging: expanding fields of vision in living subjects

  2010cites this paper
• Design of an optimized scaffold for affibody molecules.

  2010cites this paper
• Development of affinity columns for the removal of high‐abundance proteins in cerebrospinal fluid

  2009cites this paper
• Engineered protein scaffolds as next-generation antibody therapeutics.

  2009cites this paper
• Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

  2009cites this paper
• Engineered affinity proteins--generation and applications.

  2009cites this paper
• Toward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging.

  2009cites this paper
• Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule

  2009cites this paper
• Engineered affinity proteins for tumour‐targeting applications

  2009cites this paper
• Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber

  2009cites this paper
• On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model

  2009cites this paper
• Imaging of HER-2 overexpression in tumors for guiding therapy.

  2008cites this paper
• Biofunctionalized targeted nanoparticles for therapeutic applications

  2008cites this paper
• Generation of Affibody® ligands binding interleukin‐2 receptor α/CD25

  2008cites this paper
• FDG-PET and FDG-PET/CT in breast cancer.

  2008cites this paper
• Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.

  2008cites this paper
• Differences in radiosensitivity between three HER2 overexpressing cell lines

  2008cites this paper
• Application of PET/CT in the development of novel anticancer drugs.

  2008cites this paper
• Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.

  2008cites this paper
• Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression.

  2008cites this paper
• Imaging and cancer: A review

  2008cites this paper
• Affibody molecules for proteomic and therapeutic applications

  2008cites this paper
• PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.

  2008cites this paper
• Bioimaging for analysis of protein expression in cells and tissues using affinity reagents

  2008cites this paper
• EGFR and HER2 targeting for radionuclide-based imaging and therapy : preclinical studies.

  2008cites this paper
• Protein complementation assay as a display system for screening protein libraries in the intracellular environment

  2008cites this paper
• Affibody molecules targeting the epidermal growth factor receptor for tumor imaging applications

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 350 EGFR and HER 2 Targeting for Radionuclide-Based Imaging and Therapy Preclinical Studies

  2008cites this paper
• Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.

  2007cites this paper
• Photoacoustic Imaging of Multiple Targets Using Gold Nanorods

  2007cites this paper
• Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases.

  2007cites this paper
• Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy

  2007cites this paper
• Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.

  2007cites this paper
• Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence

  2007cites this paper